Liquid Biopsy

06/06/2026

A Blood Test Reduced Cancer Anxiety in 62% of Patients

Liquid Biopsy’s Hidden Superpower, Mental Health & Quality of Life

Emotional, unexpected angle. Nobody talks about anxiety reduction.

In the BESPOKE CRC study, ctDNA testing reduced recurrence-related anxiety in 62% of patients, particularly in those testing negative (p

05/06/2026

Scientists Just Solved Liquid Biopsy’s Biggest Problem

Volition’s Capture-Seq™, 99% Pure Cancer DNA, World First

The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first, Volition developed Capture-Seq™ and produced >99% pure cancer-derived plasma DNA sequence sets for liquid biopsy, virtually isolating only the tumor signal from blood.

In two independent cohorts Volition reported no false positives and detected 49/49 cancers in the first cohort, including 23 early stage I/II, and validated it in a second blinded cohort with 13/14 later stage cancers detected. Then just one week later, Volition announced >95% detection of early-stage cancers using Capture-Seq™.



For more read 📚

- https://lnkd.in/eT-PMmef

- https://lnkd.in/e5WDTJCk

04/06/2026

04/06/2026

Liquid biopsy has emerged as a transformative tool in precision oncology, offering a minimally invasive approach for cancer detection, monitoring, and treatment guidance. Unlike traditional tissue biopsies which are invasive and limited by tumor accessibility and sampling bias, liquid biopsy enables real-time tumor assessment through the analysis of circulating biomarkers in blood and other biofluids.

But a key challenge remains: liquid biopsy is less sensitive than imaging in early tumor stages, but is more specific and may help detect treatment response earlier than RECIST criteria. Cell-free and circulating tumor DNA are the most frequently tested liquid biopsy analytes and have shown promise for cancer screening, assessment of residual disease after treatment, and clinical outcome prediction.

Clinical studies demonstrate the potential of liquid biopsy for tailoring targeted therapies, predicting resistance mechanisms, and identifying tumor recurrence earlier than conventional methods, with emerging AI-based approaches enhancing sensitivity, specificity, and scalability of assays across diverse healthcare settings.



For more read 📚
- https://lnkd.in/e7xhy_Rn
- https://lnkd.in/e2TU8-p4
- https://lnkd.in/ef4mSQs8

02/06/2026

Radiopharmaceutical therapy targeting prostate-specific membrane antigen (PSMA) has been increasingly used in clinical practice since its approval for patients with metastatic castration-resistant prostate cancer in 2022. Liquid biopsy is now evolving as a promising addition in the evaluation of PSMA therapy.

In a prospective proof-of-principle study of 20 patients treated with lutetium PSMA-617, 20% of CTC samples showed no PSMA expression despite unequivocal PSMA expression of solid metastases on PET, and a high fraction of PSMA-negative CTCs was linked to both shorter overall and shorter progression-free survival. This means liquid biopsy can catch what nuclear medicine scans miss, a remarkable convergence of two cutting-edge fields.



For more read 📚
- https://lnkd.in/e5xQ9ADw

01/06/2026

Nanosensors + AI: The Lab-on-a-Chip That Finds Ovarian Cancer Early

Graphene Nanosensor + AI Active Learning for Ovarian Cancer Detection

A 2025 study published in Cells developed and validated graphene-based optical nanobiosensors that quantify the activities of a panel of proteases to create a “crowd response” specific for ovarian cancer. The panel showed statistically significant differences in protease activities when comparing localized early-stage ovarian cancer with both metastatic and healthy control groups.

A hierarchical framework integrated with active learning as a prediction and analysis tool for early-stage ovarian cancer detection was implemented, representing a fusion of nanotechnology, liquid biopsy, and AI that could transform how one of the hardest-to-detect cancers is identified from blood.

Separately, a nano sensor array using quantum-modified carbon nanotubes to analyze ovarian cancer biomarkers from serum, using five AI classifiers and 269 serum samples, demonstrated 95% accuracy, underscoring the power of combining nanosensors with machine learning for blood-based cancer detection.



For more read 📚
- https://lnkd.in/gDHygtSQ
- https://lnkd.in/eAi4g68B

30/05/2026

Medicare Now Covers Your Blood Test for Colon Cancer Recurrence

Medicare expanded its coverage of the Guardant Reveal liquid biopsy test to include colorectal cancer surveillance after curative treatment , January 2025

Guardant Health announced that Palmetto GBA, a Medicare administrative contractor, granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer following curative intent therapy. Guardant Reveal runs on Guardant’s Smart Liquid Biopsy platform and uses epigenomic methylation analysis to detect circulating tumor DNA as a marker of minimal residual disease, to predict cancer recurrence and guide clinical decisions after surgery or chemotherapy.

The tissue-free approach addresses a critical need for cancer patients who have no tissue available or for whom tissue specimens are difficult to obtain.



For more read 📚
- https://lnkd.in/d8DNSxAP
- https://lnkd.in/ezAmjHyy

29/05/2026

Prostate Cancer’s PSA Problem, And How ctDNA Is Solving It

Liquid Biopsy in Advanced Prostate Cancer, April 2026 Review

A review published in Cancers (MDPI) in April 2026 found that liquid biopsy is transforming prostate cancer management by enabling non-invasive analysis of tumor-derived material in blood. Among liquid biopsy analytes, ctDNA is the most clinically advanced, supporting biomarker testing, treatment selection, and prognosis, especially in metastatic disease.

Circulating tumor cells and extracellular vesicles provide additional prognostic and biological insights, including AR-V7 detection and RNA-based biomarkers, giving clinicians a multi-layered view of prostate cancer biology that PSA testing alone cannot provide.

And critically, a February 2026 review highlighted that while liquid biopsy has transformed advanced prostate cancer management, its clinical role in non-metastatic disease remains uncertain, with ctDNA showing emerging prognostic relevance as a marker of minimal residual disease and biological aggressiveness, pending validation in prospective trials.



For more read 📚
- https://lnkd.in/etth3Kr2
- https://lnkd.in/e8duWvCx